Hormone Therapy
Subcutaneous testosterone effective HT for transgender male, gender-diverse youths
Subcutaneous testosterone was effective in allowing transgender male and gender-diverse youths to reach recommended testosterone levels and stop menses, with few severe adverse events, according to findings published in Transgender Health.
Supporting transgender care: A conversation with Frances J. Hayes, MD, MBBCh
Author of the Endocrine Society’s Clinical Practice Guideline on testosterone therapy for hypogonadism, Frances J. Hayes, MD, MBBCh, is nationally recognized for her expertise in testosterone deficiency.
Gender-affirming HT influences HDL cholesterol levels in adolescents
Gender-affirming hormone therapy causes changes in HDL cholesterol levels for transgender adolescents, and obesity can modify these associations, according to a research letter published in JAMA Pediatrics.
Monitoring liver enzymes unnecessary during gender-affirming HT
The incidence of abnormal liver enzymes among transgender men and women prescribed gender-affirming hormone therapy is low, with no cases of symptomatic liver injury observed after 1 year of treatment, data show.
Estradiol levels higher with injection vs oral, transdermal HT for transgender women
Intramuscular injections resulted in higher levels of estradiol than oral and transdermal routes for transgender women, whereas all hormone therapy routes result in similar testosterone levels in transgender men, according to study data.
Exercise, not hormone therapy, improves vascular function in middle-aged men
A supervised center-based exercise training program, not testosterone therapy, improved vascular function among middle-aged men with central adiposity, according to research published in Hypertension.
Testosterone therapy may prevent type 2 diabetes in men without hypogonadism
Compared with placebo, 2 years of testosterone therapy was associated with lower risk for type 2 diabetes among men with impaired glucose tolerance or newly diagnosed diabetes but no hypogonadism, according to trial data.
Risk for retinal vascular occlusion not increased with female hormone therapy use
Registry highlights ‘evolving characteristics’ of patients with PAH
The U.S. Pulmonary Hypertension Scientific Registry provides novel insights on patient characteristics, diagnosis delays and treatment trends in adults with pulmonary arterial hypertension.
No increased VTE risk with continued HT during gender-affirming surgery
Transgender and gender nonbinary patients who remain on estrogen hormone therapy during gender-affirming surgery do not have an increased risk for venous thromboembolism, according to findings published in The Journal of Clinical Endocrinology & Metabolism.